Global Shingles Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Product (Shingrix, Zostavax, and Skyzoster), By Vaccine Type (Recombinant Vaccine and Live Attenuated Vaccine), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Shingles Vaccine Market Insights Forecasts to 2035

• The Global Shingles Vaccine Market Size Was Estimated at USD 5.1 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 15.8% from 2025 to 2035
• The Worldwide Shingles Vaccine Market Size is Expected to Reach USD 25.6 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights & Consulting, the Global Shingles Vaccine Market Size was worth around USD 5.1 Billion in 2024 and is predicted to Grow to around USD 25.6 Billion by 2035 with a compound annual growth rate (CAGR) of 15.8% from 2025 and 2035. Increased knowledge of the advantages of vaccinations, broader immunisation programs, and the growing frequency of shingles, particularly in elderly persons and immunocompromised people, are the main drivers of growth.

Market Overview

The shingles vaccine market encompasses products and services designed to prevent herpes zoster through immunisation. It includes vaccine development, distribution, and delivery across a variety of healthcare settings.  The market for shingles vaccines is expanding steadily due to developments in vaccine technology, such as recombinant vaccines that provide increased safety and efficacy. The WHO estimates that by 2050, there will be 2.1 billion individuals above 60 in the world, which will greatly increase demand due to older people are more susceptible to shingles and associated complications. The need for effective immunisation is further fuelled by the prevalence of immunocompromising diseases, including cancer and HIV. Improved vaccination formulations, including better adjuvants and delivery systems, have been made possible by ongoing research, which strengthens older persons' immune responses. Emerging markets are receiving additional assistance for growth through government-led adult immunization programs and improved healthcare infrastructure. Public-private partnerships and greater funding are speeding the clinical evaluation of vaccines and access across the world. Adoption of the shingles vaccine is being driven by government vaccination programs, public awareness initiatives, and advancements in vaccine formulation. While education initiatives lessen hesitancy and encourage immunization among high-risk groups, improved healthcare infrastructure and stable formulations improve accessibility and distribution, especially in emerging nations. SK Bioscience's SKYZoster approvals in Malaysia and Thailand, the market continues to expand globally. 

Report Coverage

This research report categorizes the shingles vaccine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the shingles vaccine market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the shingles vaccine market.    

Driving Factors

The inclusion of vaccinations in national immunisation programs, particularly in industrialised nations like the United States, the United Kingdom, Australia, and Italy, is what propels the market for shingles vaccines. Uptake is boosted by increased awareness among people over 60. Safety, effectiveness, and durability are improved by technological developments, such as the move to recombinant and mRNA-based vaccinations. Digital tracking technologies, adjuvant optimisation, and lyophilised mRNA are examples of innovations that enhance vaccination delivery and patient satisfaction. Market expansion is accelerated via strategic alliances and licensing contracts, which also promote innovation and worldwide accessibility.

Restraining Factors

The high cost of the shingles vaccine restricts its availability, particularly in low- and middle-income nations with limited healthcare resources. Immunisation rates are further decreased by vaccine hesitancy, which is exacerbated by false information and a lack of awareness. Furthermore, cold chain storage presents logistical difficulties in isolated and resource-constrained locations, impacting vaccine efficacy and availability as well as impeding wider market expansion and immunisation coverage.

Market Segmentation

The shingles vaccine market share is classified into product and vaccine type.

• The shingrix segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the shingles vaccine market is divided into shingrix, zostavax, and skyzoster. Among these, the shingrix segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Shingrix relies on a recombinant, adjuvanted formulation of vaccine that provides better efficacy and longer-lasting protection than standard live attenuated vaccines, and this is the reason for the leadership. The adoption and acceptance of Shingrix have exploded with the inclusion of vaccinations into adult vaccination programs and authorization of Shingrix by health authorities. The vaccination is the recommended option for healthcare professionals as well as patients because it has been demonstrated to be effective in preventing shingles and postherpetic neuralgia.  

• The recombinant vaccine segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the vaccine type, the shingles vaccine market is divided into recombinant vaccine and live attenuated vaccine. Among these, the recombinant vaccine segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Recombinant vaccines are superior because they have better efficacy and safety profiles than traditional live attenuated vaccines. Recombinant vaccines, especially Shingrix and SkyZoster, are especially beneficial for older and immunocompromised patients because they leverage modern science to mount a more robust immune response. Recommendations from respected health authorities around the world, such as Health Canada and relations to vaccine programs in numerous countries, help give growth to the dominant segment in the market. It is also expected that ongoing research to enhance adjuvants and recombinant vaccine formulations will also support the leadership of this sector throughout the timeline.

Regional Segment Analysis of the Shingles Vaccine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the shingles vaccine market over the predicted timeframe.

North America is anticipated to hold the largest share of the shingles vaccine market over the predicted timeframe. Due to its strong health system, increased awareness, and established use of advanced vaccine technology, North America is the largest segment in the shingles vaccine market. Government vaccination programs generally create a demand for the vaccines, particularly for older adults and immunocompromised individuals. Regulatory approvals in North America are rapid, and there is consistent reinvestment into vaccine development. In the US, adult vaccination campaigns have increased with the endorsement of the CDC and increased supply of vaccines to support additional uptake. In addition, North America has established vaccine makers that continue to grow their distribution systems and expand their portfolio of vaccines, which continues to support their dominance in the market for shingles vaccines.

Asia Pacific is expected to grow at a rapid CAGR in the shingles vaccine market during the forecast period. The shingles vaccine market in Asia-Pacific is growing rapidly because of the extensive at-risk population, improved access to healthcare, and the increasing disposable incomes. The adoption of vaccines is influenced by governmental initiatives, improved vaccination legislation, and increased public awareness, particularly in low- and middle-income countries. The attractiveness of the vaccines is generally underpinned by biotechnological advances, NMPA regulatory approval, and strong government support, making the market attractive for China. Japan's demographics as an older population, encouragement for vaccination, and an immunization campaign guided by the PMDA further support demand. The region's prominence in global shingles vaccine uptake is further enhanced by the expected regulatory approval for recombinant vaccines and ongoing evolution.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the shingles vaccine market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Merck & Co., Inc.
• SK bioscience
• Curevo In
• GeneOne Life Science
• GlaxoSmithKline plc.
• Pfizer Inc.
• CanSinoBIO
• Vaccitech
• Green Cross Corp
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In March 2025, the U.S. Food and Drug Administration (FDA) approved AIM Vaccine Co., Ltd.'s independently generated mRNA shingles vaccine in a clinical trial. The FDA has given AIM permission to start clinical studies for two important mRNA vaccine candidates: the mRNA RSV and mRNA shingles vaccines.

• In January 2023, SK Bioscience declared that Malaysia's National Pharmaceutical Regulatory Agency (NPRA) had approved its biologics licence application (BLA) for its shingles vaccine, SKYZosterTM. After Thailand in May 2020, this is the vaccine's second foreign approval.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the shingles vaccine market based on the below-mentioned segments:  

Global Shingles Vaccine Market, By Product

• Shingrix
• Zostavax
• Skyzoster

Global Shingles Vaccine Market, By Vaccine Type

• Recombinant Vaccine
• Live Attenuated Vaccine

Global Shingles Vaccine Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa